Danaher Corporation (NYSE:DHR) is among the 14 Best Large Cap Stocks to Invest In Now. Goldman Sachs initiated coverage on December 9, rating the stock a Buy with a price target of $265. The firm highlighted Danaher’s $6 billion bioprocessing franchise and expects growth in the pharmaceutical industry. KeyBanc also praised Danaher’s role in the Life Sciences Tools & Services industry recovery and sees potential for 3-6% core revenue growth. Danaher is a global leader in life sciences and diagnostics innovation.

Read more at Yahoo Finance: Goldman Sachs and KeyBanc are Bullish on Danaher (DHR)